Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_assertion type Assertion NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_head.
- NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_provenance.
- NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_assertion evidence source_evidence_literature NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_provenance.
- NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_assertion SIO_000772 15248218 NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_provenance.
- NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_assertion wasDerivedFrom befree-2016 NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_provenance.
- NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_assertion wasGeneratedBy ECO_0000203 NP451651.RADfotdcbIiLYY5st8PbCLokydq6Wzg2YP1nO_ktrgj8g130_provenance.